

Questions to ask your doctor:

Questions about your diagnosis

- What kind of cancer do I have?
- What is HER2 positive cancer?
- What stage is my cancer and how does it affect my treatment options?

What are my treatment options?

- How long will I need to stay on these treatments?
- How will I know this treatment is working?
- What are the chances my cancer will come back after treatment?

How will Perjeta help me?

- How long will I need to be on Perjeta?
- How will I know if the treatment is working?
- What side effects can I expect to have?

NOTES:



Perjeta® (pertuzumab), 420mg vial, is a **Prescription Medicine** used to treat early breast cancer before surgery (neoadjuvant) or metastatic (spreading) breast cancer. It is only used for patients whose tumour has tested positive to HER2.

Tell your doctor if: you have a history of heart problems such as heart failure, cardiac arrhythmias (an abnormal or rapid heartbeat), poorly controlled high blood pressure, or a recent heart attack; you have previously received chemotherapy treatment with medicines known as anthracyclines; you have experienced heart problems during previous treatment with Herceptin (trastuzumab); you have inflammation of the digestive tract, e.g. sore mouth or diarrhoea; you are pregnant or breast-feeding, or plan to become pregnant or breast-feed.

Tell your doctor immediately or go to your nearest Accident and Emergency Centre if you notice any of the following: swelling of your face, lips, tongue or throat with difficulty breathing; swelling of other parts of your body such as your hands or feet; shortness of breath, wheezing or trouble breathing; severe chest pain, spreading out to the arms, neck, shoulder or back; abnormal or irregular heartbeat; rash, itching or hives on the skin; fever or chills or severe coughing. **Possible common side effects may also include:** diarrhoea (loose or frequent stools) or constipation; sore mouth, throat or gut; getting tired more easily after light physical activity; shortness of breath especially when lying down or being woken from your sleep with shortness of breath; nail problems; hair loss; feeling dizzy, tired, looking pale; frequent infections with fever, severe chills, sore throat or mouth ulcers; eye problems such as producing more tears; insomnia (trouble sleeping); weak, numb, tingling or prickling sensations mainly affecting the feet and legs; loss of appetite; loss of or altered taste; joint or muscle pain or muscle weakness.

Perjeta has risks and benefits. Ask your oncologist if Perjeta is right for you. Use strictly as directed. If symptoms continue or you have side effects, see your healthcare professional. For further information on Perjeta, please talk to your health professional or visit www.medsafe.govt.nz for Perjeta Consumer Medicine Information.

Perjeta is a funded medicine for patients with HER2-positive metastatic breast cancer who meet pre-defined criteria.

Perjeta is not a PHARMAC funded medicine for the neoadjuvant treatment of early breast cancer.

A prescription charge and normal Doctor's fees may apply.

Consumer panel dated 08 March 2017 based on CMI dated 02 March 2017.

Roche Products (New Zealand) Limited, Auckland. Phone: 0800 656 464. www.roche.co.nz.

All trademarks mentioned herein are protected by law.